Company intelligence
RNAlead
Unlocking the Future of RNA therapeutics
About RNAlead
At RNAlead, our mission is to provide our partners with a proprietary RNA delivery technology that is powerful, versatile, and proven. We support our clients throughout their innovation journey — from early-stage research to clinical applications — with a turnkey solution designed to meet the evolving demands of modern gene and cell therapy. We are continuously optimizing our platform to enable targeted delivery to specific cell types in vivo, expanding its therapeutic potential and real-world impact.
Verified activity
Signals from RNAlead
4 published signals
Capital & Finance
RNAlead company BrainChild Bio secured a $116M Series A funding round to take a pediatric brain tumor CAR-T into a pivotal study.
Reported by Aaron Edwards
Products & Services
RNAlead launched KiraGen Bio's new website featuring the lead program KGEN-001 and design engine KiraLOGIC.
Reported by Aaron Edwards
Presence & Recognition
RNAlead announced that the CAR-TCR Summit Series will be held in Boston in two weeks.
Reported by Aaron Edwards
Presence & Recognition
RNAlead will participate in the in vivo CRISPR therapeutics event at the CMN x CSGCT Virtual Symposium on Thursday, September 3, 2026, from 13:00–15:00 CEST and 19:00–21:00 CST.
Reported by Christine Duthoit, PhD